leadf
logo-loader
viewValiRx PLC

ValiRx receives notification of patent grant allowance in New Zealand for VAL401

ValiSeek Limited, the joint venture between ValiRx and Tangent Reprofiling Limited has received notification of a New Zealand patent grant allowance.

Patent
ValiSeek was formed to progress the drug VAL401 through its remaining pre-clinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications

ValiSeek Limited, the joint venture between ValiRx Plc (LON:VAL) and Tangent Reprofiling Limited, has received notification of a New Zealand patent grant allowance.

The patent, granted in the US as patent US9072743 on 14 May 2015, covers both the formulation of VAL401 and its use as a treatment against hormone-related cancers, including lung cancer.

"This is the first non-US patent grant allowance received for the VAL401 project and, as such, it provides an international validation of the programme to support world-wide commercialisation," said Dr Suzanne Dilly, the chief executive officer of ValiSeek Limited.

 

Quick facts: ValiRx PLC

Price: 20.5 GBX

AIM:VAL
Market: AIM
Market Cap: £136.64 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

DDH1 Limited debuts on ASX following $150 million fundraise

DDH1 Limited's (ASX:DDH) Sy Van Dyk speaks to Proactive's Andrew Scott following its successful listing on the ASX in what was one of the largest IPOs by a Western Australia-based business in the past decade. DDH1 raised $150 million from new investors at $1.10 per share. He says they're now...

3 hours, 49 minutes ago

2 min read